Stomach Cancer Trial, Recruiting NCT06846996 Sponsor: Daiichi Sankyo Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT06846996
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with locally advanced, inoperable, or metastatic stomach cancer or gastroesophageal junction cancer (where the stomach meets the food pipe) confirmed by laboratory testing.
  • People who are 18 years of age or older at the time of starting the study drug and signing the consent form, and who are able to give informed consent.
  • People whose cancer tests show HER2-positive status (a specific protein level measured by laboratory tests, recorded as IHC 3+, or IHC 2+ with a second confirming test called ISH+).
  • People who have already received prior cancer treatment as recommended under national medicine authority guidelines or as decided by their treating doctor.
  • People for whom a doctor has decided to start the study drug (T-DXd) before joining the trial, or who started the study drug no more than 21 days before enrolling, provided a signed and dated consent form can be obtained.

Who may not be able to join:

  • People who are pregnant or currently breastfeeding.
  • People who are currently taking part in, or have previously taken part in, another interventional clinical trial that is still blinded (meaning the results or treatment assignment have not yet been revealed).
  • People who are known to have a serious allergy or sensitivity to the study drug or any of its ingredients.
  • People whom the trial investigator considers unfit to participate in the study for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Project Manager, Daiichi Sankyo Co., Ltd.

Phone: 908-992-6400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Daiichi Sankyo
Registry
ClinicalTrials.gov
Start date
27 February 2025
Est. completion
31 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Real-world Time to Treatment Failure (rwTTF)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov